Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

Key facts

Sponsor

Anne Comi, MD

Principal Investigator

Anne M Comi, MD

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Intervention

Cannabidiol(drug)

Enrollment

11 enrolled

Eligibility

3-50 years · All sexes

Timeline

2019 – 2022

Study locations (1)

• Kennedy Krieger Institute, Baltimore, Maryland, United States

Collaborators

Jazz Pharmaceuticals · Faneca 66 Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Sturge-Weber syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT04717427
  Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome
  University of Illinois at Chicago
• ACTIVE NOT RECRUITINGNANCT04517565
  Longitudinal Neuroimaging in Sturge-Weber Syndrome
  Wayne State University
• ACTIVE NOT RECRUITINGNCT01425944
  Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome
  Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

See all trials for Sturge-Weber syndrome →